NOVO NORDISK A/S |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,007 DKK | -2.04% |
|
+3.16% | +44.99% |
| 04:57pm | Novo Nordisk makes impairment loss of $816 million in Q2 | RE |
| 01:56pm | AlphaValue/Baader Europe Downgrades Novo Nordisk to Add from Buy, Raises PT | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
Pharmaceuticals
Calendar
2024-08-07
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
1,028
DKK
Average target price
938.1
DKK
Spread / Average Target
-8.74%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +44.99% | 654B | |
| +55.25% | 815B | |
| -6.71% | 354B | |
| +21.62% | 337B | |
| +10.15% | 302B | |
| +18.02% | 247B | |
| +2.33% | 229B | |
| +13.17% | 219B | |
| +9.71% | 171B | |
| -3.54% | 159B |
- Stock Market
- Equities
- NOVO B Stock
- News Novo Nordisk A/S
- Novo Nordisk CEO to Testify on High Prices of Ozempic, Wegovy in US Senate Hearing
